



Notification of Change

April 13, 2021

Shenandoah Biotechnology
103 Steam Whistle Drive, Suite A
Warminster, PA 18974

To whom it may concern,

Shenandoah is sending this notice to inform our customers of a change to the product specification of the following recombinant proteins; Human BDNF and Human BDNF (AF) (catalog numbers 100-01 and 100-01AF), Human/Mouse NT-3 and Human/Mouse NT-3 (AF) (catalog numbers 100-99, 100-99AF, 800-06 and 800-06AF), and Human NT-4 and Human NT-4 (AF) (catalog numbers 100-33 and 100-33AF) . All other previous product details and specifications will not change. All quality control testing has been completed and approved.

Change 1- Biological Assay:

Human BDNF

Previous Bioassay:	Rat C6 glioma cell proliferation	ED50 ≤ 2 ug/mL (≥ 5.0 x 10 ² units/mg)
New Bioassay:	Proliferation of a neuroblastoma cell line stably expressing TrkB (BR6)	ED50 ≤ 40 ng/mL (≥ 2.5 x 10 ⁴ units/mg)

Human/Mouse NT-3

Previous Bioassay:	None	
New Bioassay:	Proliferation of a neuroblastoma cell line stably expressing TrkB (BR6)	ED50 ≤ 20 ng/mL (≥ 5.0 x 10 ⁴ units/mg)

Human NT-4

Previous Bioassay:	None	
New Bioassay:	Proliferation of a neuroblastoma cell line stably expressing TrkB (BR6)	ED50 ≤ 20 ng/mL (≥ 5.0 x 10 ⁴ units/mg)

This change will take effect for all lots (both new and current) of recombinant Human BDNF, recombinant Human/Mouse NT-3 and recombinant Human NT-4. Documentation has been updated to reflect this change.

Please contact me if there are any issues or concerns.

Thank you,

Martin P. Keough, PhD
Chief Scientific Officer
martyk@shenandoah-bt.com
215-672-7550

cc.
Jazmine George
Senior Quality Scientist
jazmineg@shenandoah-bt.com
215-672-7550